drugset / Trial / NCT05962840
Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)
Phase 4
Recruiting
40 enrolled
Chinese SLE Treatment And Research Group
Peking Union Medical College Hospital · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
This study is a prospective, open-labelled, randomized, controlled, single-center clinical trial. The aim of this study is to investigate the remission rate of patients treated with Telitacicept combined with Rituximab in remission-induction and Telitacicept alone in remission-maintain treatment.
Timeline
- Start
- 2023-06-29
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Telitacicept | Protein / enzyme biologic | 80 mg | Subcutaneous |